S1P Receptor Modulators: The Latest Evidence & Clinical Strategies for Ulcerative Colitis

Intended Audience: Gastroenterologists, internal medicine physicians, primary care physicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), nurses, and pharmacists

The therapeutic landscape for ulcerative colitis (UC) is rapidly expanding to include treatments with novel mechanisms of action. Among these are the sphingosine-1 phosphate (S1P) receptor modulators, a new class of small molecule therapies for patients with moderately to severely active disease.

In this video, hear leading experts discuss the latest clinical evidence and practical strategies for integrating S1P receptor modulators into practice and see how your knowledge compares with that of other clinicians in interactive questions and case-based scenarios.

Don't miss this dynamic discussion and opportunity to:

• Review advances in our understanding of UC pathophysiology and novel treatment targets illustrated through video animation
• Hear experts analyze the latest clinical evidence and discuss applications for new and emerging S1P receptor modulators for UC
• Assess your knowledge on the optimal use of novel therapies in clinical cases and see how your skills stack up with other providers

• Differentiate the inflammatory pathways and mediators involved in the pathogenesis of ulcerative colitis (UC)
• Recognize the role of oral small molecule inhibitors in the evolving UC pharmacologic landscape
• Evaluate new and emerging targeted therapies for UC based on the latest clinical efficacy and safety data, as well as their mechanisms of action and routes of administration
• Develop guideline-informed and personalized UC management plans that integrate patient- and disease-specific factors into treatment decisions

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.75 contact hour (which includes 0.62 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Arun Swaminath, MD (Speaker)
  
  Grants / Research Support – AbbVie, Janssen
  Other Financial or Material Support (royalties, patents, etc.) – Janssen, Pfizer, Takeda
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• David P. Hudesman, MD (Speaker)
  
  Advisory Board or Panel – AbbVie, Bristol-Myers Squibb, Fresenius Kabi, Janssen Biotech, Pfizer, Prometheus, Takeda
  Consultant – AbbVie, Bristol-Myers Squibb, Fresenius Kabi, Janssen Biotech, Pfizer, Prometheus, Takeda
  Grants / Research Support – Janssen Biotech, Pfizer
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  
  Speakers Bureau or other Promotional Education – AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Dova, Eli Lilly and Company, Gilead Sciences
  The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP (Reviewer)
• Jason Welch, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.